Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 7
The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.
Video Player is loading.
Related Content:
